Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Version 2 2021-09-28, 02:13
Version 1 2021-09-22, 08:46
online resource
posted on 2021-09-28, 02:13 authored by Yvette LambDeclarations
Funding The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest Yvette Lamb is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable
Additional information about this Adis Drug Review can be found here
Abstract
Funding The preparation of this review was not supported by any external funding.
Authorship and Conflict of interest Yvette Lamb is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.
Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable
Additional information about this Adis Drug Review can be found here
Abstract
Activating mutations in the epidermal growth factor receptor (EGFR) gene have been identified as key oncogenic drivers
of non-small cell lung cancer (NSCLC). Osimertinib (Tagrisso®) is an orally administered, third-generation EGFR tyrosine
kinase inhibitor (EGFR-TKI) that is widely approved for the first-line treatment of advanced NSCLC with activating EGFR
mutations. In the pivotal phase III FLAURA trial, osimertinib significantly prolonged progression-free survival (PFS) and
overall survival (OS) relative to first-generation EGFR-TKIs in patients with previously untreated, EGFR mutation-positive,
advanced NSCLC. Osimertinib also significantly prolonged central nervous system (CNS) PFS in patients with CNS metastases at trial entry. Osimertinib had a generally manageable tolerability profile; the majority of adverse events considered
to be possibly related to treatment were of mild to moderate severity. Osimertinib represents a valuable targeted therapeutic
for use in adults with previously untreated, EGFR mutation-positive, advanced NSCLC.
A plain language summary slide is shown above.
© Springer Nature Switzerland AG 2021
© Springer Nature Switzerland AG 2021
